# PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

> **NCT06639607** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 68 (estimated)

## Conditions studied

- Diffuse Midline Glioma
- Diffuse Midline High-grade Glioma
- Medulloblastoma
- Ependymoma

## Interventions

- **BIOLOGICAL:** PEP-CMV vaccine
- **BIOLOGICAL:** Tetanus booster
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT06639607
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2031-06-30
- **Final completion:** 2043-04-30
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06639607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06639607, "PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06639607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*